Clinical Trial

Evaluation of the Effectiveness of a Mobile Application Developed for Hemodialysis Patients.

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 7, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to evaluate the effectiveness of a mobile health application developed for adult patients undergoing hemodialysis treatment. The mobile application includes modules on adherence to medication, diet, and fluid restrictions, symptom management (fatigue, pain, itching), nutrition guidance, exercise recommendations, and motivational content. It also features reminder notifications, an "Ask the Expert" module, and personal symptom tracking. The research will be conducted as a single-center, single-blind, randomized controlled experimental study. Participants will be assigned to intervention and control groups using block randomization. The intervention group will receive the mobile application, while the control group will receive standard care. Assessments will be carried out at baseline (T0), 1st month (T1), and 2nd month (T2). The measurement tools to be used include the End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ), Post-Dialysis Fatigue Scale, 5-D Itch Scale, Visual Analog Scale (VAS) for pain, and the Mobile Application Usability Scale. In addition, clinical parameters such as serum potassium, phosphorus, and albumin will be evaluated. A total of 72 patients (36 intervention, 36 control) will be included in the study. This study aims to assess the impact of a mobile health application on treatment adherence, symptom management, and clinical parameters among hemodialysis patients, and to develop a digital health model that can be integrated into nursing care.
Trial Details
NCT Number NCT07211100
Lead Sponsor Saglik Bilimleri Universitesi
Collaborators: Gümüşhane Universıty
Conditions End-Stage Renal Disease Requiring Haemodialysis, Mobile Application
Enrollment 72 participants
Start Date 2025-11
Primary Completion 2025-12 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-10-07